158 related articles for article (PubMed ID: 27110599)
1. Aspirin-Triggered Resolvin D1 Versus Dexamethasone in the Treatment of Sjögren's Syndrome-Like NOD/ShiLtJ Mice - A Pilot Study.
Easley JT; Nelson JW; Mellas RE; Sommakia S; Wu C; Trump B; Baker OJ
J Rheum Dis Treat; 2015; 1(4):. PubMed ID: 27110599
[TBL] [Abstract][Full Text] [Related]
2. AT-RvD1 combined with DEX is highly effective in treating TNF-α-mediated disruption of the salivary gland epithelium.
Easley JT; Maruyama CL; Wang CS; Baker OJ
Physiol Rep; 2016 Oct; 4(19):. PubMed ID: 27694530
[TBL] [Abstract][Full Text] [Related]
3. Aspirin Triggered Resolvin D1 reduces inflammation and restores saliva secretion in a Sjögren's syndrome mouse model.
Dean S; Wang CS; Nam K; Maruyama CL; Trump BG; Baker OJ
Rheumatology (Oxford); 2019 Jul; 58(7):1285-1292. PubMed ID: 30877775
[TBL] [Abstract][Full Text] [Related]
4. A combination treatment of low-dose dexamethasone and aspirin-triggered resolvin D1 reduces Sjögren syndrome-like features in a mouse model.
Dos Santos HT; Maslow F; Nam K; Trump B; Weisman GA; Baker OJ
JADA Found Sci; 2023; 2():. PubMed ID: 37622089
[TBL] [Abstract][Full Text] [Related]
5. Sex-mediated elevation of the specialized pro-resolving lipid mediator levels in a Sjögren's syndrome mouse model.
Parashar K; Schulte F; Hardt M; Baker OJ
FASEB J; 2020 Jun; 34(6):7733-7744. PubMed ID: 32277856
[TBL] [Abstract][Full Text] [Related]
6. AT-RvD1 Promotes Resolution of Inflammation in NOD/ShiLtJ mice.
Wang CS; Maruyama CL; Easley JT; Trump BG; Baker OJ
Sci Rep; 2017 Mar; 7():45525. PubMed ID: 28361884
[TBL] [Abstract][Full Text] [Related]
7. Expression of resolvin D1 biosynthetic pathways in salivary epithelium.
Leigh NJ; Nelson JW; Mellas RE; Aguirre A; Baker OJ
J Dent Res; 2014 Mar; 93(3):300-5. PubMed ID: 24389810
[TBL] [Abstract][Full Text] [Related]
8. ALX/FPR2 receptor for RvD1 is expressed and functional in salivary glands.
Nelson JW; Leigh NJ; Mellas RE; McCall AD; Aguirre A; Baker OJ
Am J Physiol Cell Physiol; 2014 Jan; 306(2):C178-85. PubMed ID: 24259417
[TBL] [Abstract][Full Text] [Related]
9. Changes in the Submandibular Salivary Gland Epithelial Cell Subpopulations During Progression of Sjögren's Syndrome-Like Disease in the NOD/ShiLtJ Mouse Model.
Gervais EM; Desantis KA; Pagendarm N; Nelson DA; Enger T; Skarstein K; Liaaen Jensen J; Larsen M
Anat Rec (Hoboken); 2015 Sep; 298(9):1622-34. PubMed ID: 26179322
[TBL] [Abstract][Full Text] [Related]
10. Predictive modeling of aspirin-triggered resolvin D1 pharmacokinetics for the study of Sjögren's syndrome.
Yellepeddi VK; Baker OJ
Clin Exp Dent Res; 2020 Apr; 6(2):225-235. PubMed ID: 32250566
[TBL] [Abstract][Full Text] [Related]
11. Specialized pro-resolving receptors are expressed in salivary glands with Sjögren's syndrome.
Dos Santos HT; Nam K; Maslow F; Trump B; Baker OJ
Ann Diagn Pathol; 2022 Feb; 56():151865. PubMed ID: 34847389
[TBL] [Abstract][Full Text] [Related]
12. Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically-Based Pharmacokinetic Modeling.
Yellepeddi VK; Parashar K; Dean SM; Watt KM; Constance JE; Baker OJ
Clin Transl Sci; 2021 Mar; 14(2):683-691. PubMed ID: 33202089
[TBL] [Abstract][Full Text] [Related]
13. Resolvin D1 prevents TNF-α-mediated disruption of salivary epithelial formation.
Odusanwo O; Chinthamani S; McCall A; Duffey ME; Baker OJ
Am J Physiol Cell Physiol; 2012 May; 302(9):C1331-45. PubMed ID: 22237406
[TBL] [Abstract][Full Text] [Related]
14. Intratracheal Poly(I:C) Exposure Accelerates the Immunological Disorder of Salivary Glands in Sjogren's-Like NOD/ShiLtJ Mice.
Hu P; Ming B; Wu X; Cai S; Tang J; Dong Y; Zhou T; Tan Z; Zhong J; Zheng F; Dong L
Front Med (Lausanne); 2021; 8():645816. PubMed ID: 33928105
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-17 Impairs Salivary Tight Junction Integrity in Sjögren's Syndrome.
Zhang LW; Cong X; Zhang Y; Wei T; Su YC; Serrão AC; Brito AR; Yu GY; Hua H; Wu LL
J Dent Res; 2016 Jul; 95(7):784-92. PubMed ID: 26933138
[TBL] [Abstract][Full Text] [Related]
16. Total glucosides of paeony (TGP) alleviates Sjogren's syndrome through inhibiting inflammatory responses in mice.
Li B; Liu G; Liu R; He S; Li X; Huang L; Wang Z; Li Y; Chen Y; Yin H; Fang W
Phytomedicine; 2020 Jun; 71():153203. PubMed ID: 32402913
[TBL] [Abstract][Full Text] [Related]
17. Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice.
Bento AF; Claudino RF; Dutra RC; Marcon R; Calixto JB
J Immunol; 2011 Aug; 187(4):1957-69. PubMed ID: 21724996
[TBL] [Abstract][Full Text] [Related]
18. Blockade of CD40-CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD/ShiLtJ mouse model of Sjögren's syndrome.
Wieczorek G; Bigaud M; Pfister S; Ceci M; McMichael K; Afatsawo C; Hamburger M; Texier C; Henry M; Cojean C; Erard M; Mamber N; Rush JS
Ann Rheum Dis; 2019 Jul; 78(7):974-978. PubMed ID: 30902822
[TBL] [Abstract][Full Text] [Related]
19. Disruption of endothelial barrier function is linked with hyposecretion and lymphocytic infiltration in salivary glands of Sjögren's syndrome.
Cong X; Zhang XM; Zhang Y; Wei T; He QH; Zhang LW; Hua H; Lee SW; Park K; Yu GY; Wu LL
Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3154-3163. PubMed ID: 29981359
[TBL] [Abstract][Full Text] [Related]
20. Current experimental methods to investigate the impact of specialized pro-resolving lipid mediators on Sjögren's syndrome.
Dos Santos HT; Nam K; Gil D; Yellepeddi V; Baker OJ
Front Immunol; 2022; 13():1094278. PubMed ID: 36713415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
